In this issue:
Hyperuricemia as a risk factor for PsA
HBV reactivation after anti-TNF agents in psoriasis
Adverse events and treatment discontinuation in plaque psoriasis
Psoriasis in patients with schizophrenia
HLA-Cw6-positive patients with psoriasis
Herpes zoster after tofacitinib
Risk of malignancy in biologic-naive paediatric psoriasis
New interleukins in psoriasis and PsA patients
Adalimumab vs methotrexate in children and adolescents
Tildrakizumab vs placebo or etanercept for chronic plaque psoriasis
Please login below to download this issue (PDF)